Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Decoy Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001615219.
Disclosed value leader
CVI Investments, Inc.
Comparable rows
12/19
Latest evidence
31 Aug 2026
- Public ticker
- DCOY on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
12 of 19
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001615219
- Issuer location
- Houston, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Decoy Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
CVI Investments, Inc.
Comparable rows
12/19
Latest evidence
31 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
7 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 19 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
12 of 19 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
10%
CVI Investments, Inc.
9.9%
INTRACOASTAL CAPITAL, LLC
5%
Frederick Pierce II
5.3%
Mark J. Rosenblum
1.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 19 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
10%
|
$382,538
65,503 shares
|
$0 | 30 Jun 2026 |
| CVI Investments, Inc. |
13D/G
|
9.9%
|
$885,706
708,565 shares
|
+$432,582 | 31 Dec 2025 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
$711,721
187,295 shares
|
$0 | 12 Nov 2025 |
| Frederick Pierce II |
3/4/5
Chief Executive Officer
|
5.3%
|
$250,549
34,844 shares
|
— | 31 Aug 2026 |
| Mark J. Rosenblum |
3/4/5
Chief Financial Officer
|
1.7%
|
$81,706
11,363 shares
|
+$16,000 | 31 Aug 2026 |
| Barbara Louise Hibner |
3/4/5
Chief Scientific Officer
|
0.64%
|
$30,315
4,216 shares
|
— | 31 Aug 2026 |
| Peter Klaus Marschel |
3/4/5
Chief Business Officer
|
0.59%
|
$28,043
3,900 shares
|
— | 31 Aug 2026 |
| Patricia G. Gauthier |
3/4/5
Director
|
0.31%
|
$14,381
2,000 shares
|
— | 31 Aug 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$19,723.
Buys
$19,740
Insiders: 2
Sells
$17.27
Insiders: 1
Net
+$19,723
Shares: +24,973
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 25,000
Shares: 27
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 27 | $0 | $17.27 | -$17.27 |
| 9-12 | 25,000 | 0 | $19,740 | $0 | +$19,740 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Decoy Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Frederick Pierce II
Net 12M change
+$19,723
Latest report
31 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Frederick Pierce II | Chief Executive Officer | $250,549 | Median | 31 Aug 2026 | ||
| Mark J. Rosenblum | Chief Financial Officer | $81,706 | +$16,000 | +24% | Median | 31 Aug 2026 |
| Barbara Louise Hibner | Chief Scientific Officer | $30,315 | Median | 31 Aug 2026 | ||
| Peter Klaus Marschel | Chief Business Officer | $28,043 | Median | 31 Aug 2026 | ||
| Arnold C. Hanish | Director | $27,775 | +$3,723 | +15% | Mixed | 31 Aug 2026 |
| William K. McVicar | Director | $21,586 | Median | 31 Aug 2026 | ||
| Jonathan I. Lieber | Director | $14,395 | Median | 31 Aug 2026 | ||
| Tess Burleson | Director | $14,395 | Median | 31 Aug 2026 | ||
| Paul Lammers | Director | $14,388 | Median | 31 Aug 2026 | ||
| Patricia G. Gauthier | Director | $14,381 | Median | 31 Aug 2026 | ||
| David J. Arthur | Chief Executive Officer, Director | Mixed | 11 Apr 2024 | |||
| Bruce J. McCreedy Jr. | Director | Mixed | 20 Feb 2024 |
Recent insider transactions for Decoy Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jonathan I. Lieber | DCOY | Common Stock | Award | 100000% | 2,000 | 2,002 | 31 Aug 2026 | Direct | ||
| Frederick Pierce II | DCOY | Common Stock | Award | 2408.6% | 33,455 | 34,844 | 31 Aug 2026 | Direct | ||
| Peter Klaus Marschel | DCOY | Common Stock | Award | 3,900 | 3,900 | 31 Aug 2026 | Direct | |||
| Mark J. Rosenblum | DCOY | Common Stock | Award | 576% | 9,682 | 11,363 | 31 Aug 2026 | Direct | ||
| Barbara Louise Hibner | DCOY | Common Stock | Award | 4,216 | 4,216 | 31 Aug 2026 | Direct | |||
| Arnold C. Hanish | DCOY | Common Stock | Award | 717.7% | 3,000 | 3,418 | 31 Aug 2026 | Direct | ||
| Paul Lammers | DCOY | Common Stock | Award | 200000% | 2,000 | 2,001 | 31 Aug 2026 | Direct | ||
| Tess Burleson | DCOY | Common Stock | Award | 100000% | 2,000 | 2,002 | 31 Aug 2026 | Direct | ||
| William K. McVicar | DCOY | Common Stock | Award | 150000% | 3,000 | 3,002 | 31 Aug 2026 | Direct | ||
| Patricia G. Gauthier | DCOY | Common Stock | Award | 2,000 | 2,000 | 31 Aug 2026 | Direct | |||
| Arnold C. Hanish | SLRX | Common Stock | Sale | -100% | $7.68 | $0.6397 | -12 | 0 | 30 Dec 2025 | Direct |
| Arnold C. Hanish | SLRX | Common Stock | Sale | -0.3% | $9.6 | $0.6397 | -15 | 5,000 | 30 Dec 2025 | By Arnold C. Hanish Trust |
| Arnold C. Hanish | SLRX | Common Stock | Purchase | 33333.3% | $3,740 | $0.7481 | 5,000 | 5,015 | 20 Nov 2025 | By Arnold C. Hanish Trust |
| Mark J. Rosenblum | SLRX | Common Stock | Purchase | 11299.4% | $16,000 | $0.8000 | 20,000 | 20,177 | 20 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.